New therapies for osteoporosis: Zoledronic acid, bazedoxifene, and denosumab

Current Osteoporosis Reports

Volumn 7, Issue 3, 2009, Pages 91-95

  Silverman, Stuart L ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN; DENOSUMAB; GLUCOCORTICOID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; BONE DENSITY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM HYPERPLASIA; FLU LIKE SYNDROME; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HOT FLUSH; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY FUNCTION; LEG CRAMP; LOADING DRUG DOSE; MASTALGIA; MYALGIA; NEOPLASM; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; TREATMENT RESPONSE; VASOMOTOR DISORDER; VEIN THROMBOSIS; VERTEBRA FRACTURE;

EID: 72449187000     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-009-0015-2     Document Type: Review

References (19)

1. D.M. Black P.D. Delmas R. Eastell, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 17476007 10.1056/NEJMoa067312 1:CAS:528:DC%2BD2sXltVSktLc%3D (Pubitemid 46698462)
2. K.W. Lyles C.S. Colon-Emeric J.S. Magaziner, et al. 2007 HORIZON Recurrent Fracture Trial: Zoledronic acid in reducing clinical fracture and mortality after hip fracture N Engl J Med 357 1799 1809 17878149 10.1056/NEJMoa074941 1:CAS:528:DC%2BD2sXht1Kit7nN (Pubitemid 350044800)
3. Zoledronic acid prescribing information. Available at http://www.pharma.us.novartis.com/product/pi/pdf/reclast.pdf. Accessed June 5, 2009.
4. M. McClung R. Recker P. Miller, et al. 2007 Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate Bone 41 122 128 17468062 10.1016/j.bone.2007.03.011 1:CAS:528:DC%2BD2sXmsFKkurc%3D (Pubitemid 46901056)
5. D.M. Reid J.P. Devogelaer K. Saag, et al. 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial Lancet 373 1253 1263 19362675 10.1016/S0140-6736(09)60250-6 1:CAS:528:DC%2BD1MXktlyqtb4%3D
6. S. Ronkin R. Northington E. Baracat, et al. 2005 Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator in postmenopausal women Obstet Gynecol 105 1397 1404 15932835 1:CAS:528: DC%2BD2MXls1eitb4%3D (Pubitemid 40734275)
7. D. Van Duren S. Ronkin J. Pickar, et al. 2006 Bazedoxifene combined with conjugated estrogens: a novel alternative to traditional hormone therapies [abstract] Fertil Steril XX Suppl1 88 S89
8. I. Itabashi H. Ohta B. Ebede, et al. 2008 A double-blind, placebocontrolled, dose-response study of bazedoxifene in Japanese postmenopausal women with osteoporosis [abstract] J Bone Miner Res 23 P79
9. G. Bachmann U. Crosby R.A. Feldman, et al. 2008 Vasomotor effects of bazedoxifene in non-flushing postmenopausal women [abstract P-10] Menopause 15 1212
10. P. Boudes S. Ronkin P. Korner, et al. 2003 Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast pain [abstract] Osteoporos Int 14 4
11. C.H. Chestnut C. Christiansen H.C. Hoeck, et al. 2007 Safety and tolerability of bazedoxifene for the prevention of postmenopausal osteoporosis [abstract] J Bone Miner Res 22 W387
12. C.P. Miller C. Christiansen H.C. Hoeck, et al. 2007 Efficacy of bazedoxifene for prevention of postmenopausal osteoporosis. Results of a 2-year, phase III, placebo and active-controlled study [abstract] J Bone Miner Res 22 1209 10.1359/jbmr.070402 (Pubitemid 351339726)
13. P.D. Miller A.A. Chines C. Christiansen, et al. 2008 Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo-, and active-controlled study J Bone Miner Res 23 525 535 18072873 10.1359/jbmr.071206 1:CAS:528:DC%2BD1cXltFyhsb8%3D
14. S.L. Silverman C. Christiansen H.K. Genant, et al. 2008 Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 23 1923 1934 18665787 10.1359/jbmr.080710 1:CAS:528:DC%2BD1MXosVylsbo%3D
15. J.D. Adachi C.H. Chesnut J.P. Brown, et al. 2007 Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial [abstract] J Bone Miner Res 22 W385 10.1359/jbmr.061116 (Pubitemid 46797121)
16. P.D. Miller M.A. Bolognese E.M. Lewiecki, et al. 2008 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 222 229 18539106 10.1016/j.bone.2008.04. 007 1:CAS:528:DC%2BD1cXosVOitrk%3D
17. P.J. Bekker D.L. Holloway A.S. Rasmussen, et al. 2004 Single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 19 1059 1066 15176987 10.1359/JBMR.040305 1:CAS:528:DC%2BD2cXlvFWrtr0%3D (Pubitemid 41110556)
18. Cummings SR, McClung MR, Christiansen C, et al.: A phase III study of the effects of denosumab on vertebral, non-vertebral, and hip fractures: results from the freedom trial. J Bone Miner Res 2009 (in press).
19. Miller P: Denosumab. Curr Osteoporosis Reports 2009 (in press).